1 December 2020 - EMA’s CHMP has started a rolling review of Ad26.COV2.S, a COVID-19 vaccine from Janssen-Cilag.
The CHMP’s decision to start the rolling review is based on preliminary results from laboratory studies and early clinical studies in adults.